Oncolytics COO reports 500K stock options

ONCOLYTICS BIOTECH INC Chief Operating Officer John Bearden reported holding stock options linked to 500,000 Common Shares.

Accepted by SEC EDGAR 06/03/2026 - 04:30 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

ONCOLYTICS BIOTECH INC Chief Operating Officer John Bearden reported holding stock options linked to 500,000 Common Shares. These options have an exercise price of $0.97 per share and expire on January 12, 2031. The option vests 50% on January 12, 2027, 25% on January 12, 2028, and 25% on January 12, 2029, subject to his continued service or employment on each vesting date.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider McAdory John Bearden

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Holding	Stock Options	--	--	--

Holdings: Stock Options — 500,000 contracts (Direct)

Footnotes (1)

1. F1. The stock option vests in three installments: 50% vesting on January 12, 2027; 25% vesting on January 12, 2028; and 25% vesting on January 12, 2029, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date.

Key Figures

Underlying shares: 500,000 Common Shares Exercise price: $0.97 per share Expiration date: January 12, 2031 +3 more

6 metrics

Underlying shares 500,000 Common Shares Stock options underlying security shares reported as held

Exercise price $0.97 per share Stock option exercise price

Expiration date January 12, 2031 Stock option expiration

Vesting 50% January 12, 2027 First vesting installment (50% of option)

Vesting 25% (second) January 12, 2028 Second vesting installment (25% of option)

Vesting 25% (third) January 12, 2029 Third vesting installment (25% of option)

Key Terms

Stock Options, Common Shares, exercise price, vesting, +1 more

5 terms

Stock Options financial

"security_title: "Stock Options""

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

Common Shares financial

"underlying_security_title: "Common Shares""

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

exercise price financial

"conversion_or_exercise_price: "0.9700""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The stock option vests in three installments: 50% vesting on January 12, 2027..."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Reporting Person regulatory

"subject to the Reporting Person's continued service or employment"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider position does ONCY COO John Bearden report on this Form 3?

John Bearden reports holding stock options tied to 500,000 Common Shares of Oncolytics Biotech Inc. These options are disclosed as a derivative position, not as a recent purchase or sale of common shares in the open market.

What is the exercise price of John Bearden’s Oncolytics (ONCY) stock options?

The disclosed stock options have an exercise price of $0.97 per share. This means Bearden can acquire Common Shares at $0.97 if he exercises the options, subject to the vesting schedule and the options remaining outstanding until expiration.

When do John Bearden’s ONCY stock options vest according to the filing?

The option vests in three installments: 50% on January 12, 2027, 25% on January 12, 2028, and 25% on January 12, 2029. Each vesting tranche depends on Bearden’s continued service or employment on the respective vesting date.

What is the expiration date of the stock options reported by ONCY’s COO?

The stock options reported by John Bearden expire on January 12, 2031. After this expiration date, any unexercised portion of the options would no longer be exercisable under the terms described in the Form 3 and related footnote.

Does the ONCY Form 3 show any insider buying or selling of common shares?

The Form 3 describes a stock option holding rather than open-market buying or selling of common shares. Transaction summaries indicate no buy or sell transactions, only a holding entry for the derivative stock option position disclosed by the company’s Chief Operating Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

McAdory John Bearden

(Last) (First) (Middle)

C/O ONCOLYTICS BIOTECH INC.

4350 EXECUTIVE DRIVE, SUITE 325

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/01/2026

3. Issuer Name and Ticker or Trading Symbol
ONCOLYTICS BIOTECH INC [ ONCY ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	(1)	01/12/2031	Common Shares	500,000	$0.97	D

Explanation of Responses:

1. The stock option vests in three installments: 50% vesting on January 12, 2027; 25% vesting on January 12, 2028; and 25% vesting on January 12, 2029, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney.

	/s/ Kirk Look, Attorney-in-Fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)